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Abstract One Plasmodium falciparum malaria antigen is an
integral membrane protein called apical membrane antigen-1.
High activity binding peptides to human red blood cells have
been identi¢ed in this protein. 4337 is a conserved, non-immu-
nogenic peptide with high activity red blood cell binding and its
critical residues have already been identi¢ed. Peptide analogues
(with amino acids having the same mass but di¡erent charge)
were generated to change their immunogenic and protective
characteristics. Three analogues having positive or negative im-
munological results were studied by nuclear magnetic resonance.
The studied peptides all had an K-helix fragment, but in di¡er-
ent peptide regions and extensions, except for randomly struc-
tured 4337. We show that altering a few amino acids induced
immunogenicity and protectivity against experimental malaria
and changed their three-dimensional structure, suggesting a
better ¢t with immune system molecules and that modi¢ed pep-
tides having better immunological properties can be included
in the design of new malaria multi-component subunit-based
vaccine. ( 2002 Published by Elsevier Science B.V. on behalf
of the Federation of European Biochemical Societies.
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1. Introduction
Malaria continues to be one of the great public health
problems throughout the world, causing 300 million cases of
infection and more than 2.5 million deaths annually, mainly
children less than 5 years old in Africa. The search for cheap,
reliable control methods for this disease (such as anti-malarial
insecticides and vaccines) has thus become a target for the
main health providing entities throughout the world [1,2].
We thus attempted to block the Plasmodium falciparum
merozoite red blood cell (RBC) recepter^ligand interaction
when developing such immune^prophylactic methods [3,4].
Various proteins are excellent targets since they seem to be
involved in this interaction [5], apical membrane antigen-1
(AMA)-1 (also named Pf83/AMA-1) being one of them.
This molecule has been associated with the invasion interface
and may be involved in the merozoite’s reorientation via a
mechanism which is inverse to that of the membrane transport
[6,7].
The P. falciparum Pf83/AMA-1 protein has 622 amino acids
with a 71 929 Da mass [8]. It shows integral membrane protein
characteristics, being located in the neck of the rhoptria and is
transported to the merozoite membrane during maturation. It
has high homology among the di¡erent P. falciparum strains
[9,10].
20-mer, radio-labeled, non-overlapping, synthetic peptide
binding assays (covering the protein’s entire length) showed
that the conserved peptide coded 4337 (WGEEK-
RASHTTPVLMEKPYY), located in the protein’s C-terminal
region, bound to RBC with a 120E 12 nm a⁄nity constant
(peptide numbers given here correspond to those serial num-
bers used in our institute) [11]. The critical residues for bind-
ing to RBCs were determined by glycine substitution ana-
logues and were identi¢ed as W1, E4, H9, M15 and K17,
underlined above [11].
Since conserved sequences are poorly antigenic [12] and
poorly or non-immunogenic [13], peptides were synthesized,
critical amino acids for binding to RBCs being replaced by
amino acids having the same mass but di¡erent charge to
improve these molecules’ biological activity.
Here we present the three-dimensional structure for pep-
tides 14044, 14048 and 13814 (4337 peptide analogues) deter-
mined by 1H nuclear magnetic resonance (NMR), with pos-
itive and negative results in immunological assays. Our
purpose was to try to ¢nd correlation between these peptides’
structure and immunological function to adopt a rational ap-
proach towards synthetic, multi-component subunit-based,
malaria vaccine development.
2. Materials and methods
2.1. Animals and immunization
Groups of ¢ve to eight P. falciparum indirect immuno£uorescence
assay (IFA) negative Aotus monkeys, [14] kept in Leticia (the Amazon
Department) according to National Institute of Health guidelines for
animal handling, were subcutaneously immunized with 125 Wg poly-
merized peptide (on days 1, 20 and 40) which had been previously
homogenized with complete Freund’s Adjuvant for the ¢rst dose and
incomplete Freund’s Adjuvant for the second and third doses. Con-
trols received only Freund’s Adjuvant and saline solution on the same
days. Blood samples were drawn pre-immunization and 20 days after
the second and third doses.
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2.2. Challenge and infection assessment
Immunized and control monkeys received an intravenous injection
of 200 000 fresh P. falciparum FVO strain infected RBC 20 days after
the third dose (this being an infective dose for 100% of Aotus monkeys
[14]). Infection was assessed after day 5 by immuno£uorescence with
Acridine Orange staining. The percentage of infected RBC was read
[14]. Protection was de¢ned as being the complete absence of parasites
in the blood during the 15 days of the trial. Control and non-pro-
tected monkeys developed patent parasitemia by day 5, reaching v 6%
by days 8^10; they were then treated with pediatric doses of anti-
malarial drugs so as to be returned to the jungle 4 weeks later.
2.3. IFA and Western blot
The P. falciparum FCB-2 strain, kept in culture (Oþ RBC) accord-
ing to Lambros and Vanderberg’s method, was used [15]. 20% late
parasitemia cultures were air dried, ¢xed on slides, blocked with 1%
non-fat milk, incubated with two-fold sera dilutions (starting at 1:40),
washed and stained with anti-Aotus IgG/FITC conjugate at 1:100
dilution and then read by £uorescence microscope.
The 20% late parasitemia saponine pellet, dissolved 1:5 in Laemm-
li’s bu¡er, was electrophoretically separated, transferred to nitrocellu-
lose paper and incubated with 1:100 diluted pre-immune or immune
sera for Western blot analysis. The reaction was revealed with a⁄nity
puri¢ed goat anti-Aotus IgG-alkaline phosphatase conjugate.
2.4. Peptide synthesis
20 amino acid long peptides were synthesized by standard Solid
Phase Peptide Synthesis technique [16], puri¢ed by HPLC and char-
acterized by RP-HPLC and mass spectrometry, the expected theoret-
ical mass being found. CG was added at the peptides’ N- and
C-termini to allow polymerization by oxidation for use in immuniza-
tion studies. This procedure was carefully standardized to guarantee
the inclusion of high molecular weight polymers; some peptides were
also synthesized as dendrimers [17].
2.5. NMR
All NMR experiment samples were prepared by dissolving 10 mg
peptide in 500 Wl 2,2,2,-tri£uoroethanol^d3/H2O mixture (30/70 v/v)
[18]. 1H spectra were acquired on a BRUKER DRX-500 spectrometer
at 295 K. Proton spectra were assigned by double quantum ¢ltered
correlation spectroscopy (DQF-COSY) [19] and total correlation spec-
troscopy (TOCSY) [20]. Inter-proton nuclear Overhauser e¡ects
(NOEs) were determined by phase sensitive NOESY (NOE spectros-
copy) [21]. Assignments were done according to Wu«thrich’s standard
procedure [22]. TOCSY spectra recorded at di¡erent temperatures
(285^315 K) were used to obtain amide temperature coe⁄cients for
predicting hydrogen bonds (3vNHN/vT6 4). DQF-COSY spectra
spin coupling constants (3JHNHK) were measured.
2.6. Structure calculations
Structure was determined by using a combination of distance ge-
ometry and simulated annealing (Molecular Simulations Inc., DGII
program and Discover programs, respectively). NOE peaks, selected
from 400 ms NOESY data sets, were integrated and converted into
distance restraints. These restraints were grouped as strong, medium
and weak corresponding to 1.8^2.5 AV ; 2.5^3.5 AV ; and 3.5^5.0 AV
distance restraints respectively. Strong NOE intensities between the
two Pro18 HN protons (1.79 AV ) set the standard for relative intensity
calibration. Hydrogen bond constraints were introduced for low
amide temperature coe⁄cients; only 6 43vNHN/vT ppb/K were
used in structure calculations.
Distance ranges involving these likely NHTO hydrogen bonds were
set at 1.8^2.5 AV between the residue acceptor oxygen (i-4) and the
residue donor amide hydrogen (i). The P angle constraints derived
from 3JHNHK were restricted to 370E 30‡ if 3JHNHK 6 6 Hz.
All peptide bonds were forced to trans and CK chirality to L during
calculations. A non-bonded 8 AV cut-o¡ distance was used; no charges
nor cross terms were included. Only those structures having reason-
able geometry and low constraint violation were retained. The re-
strained simulated annealing protocol (Discover 2.98) consisted of
eight phases. These included raising the initial temperature to
1000 K for 12 ps in three phases. The system was then cooled to
300 K. Four energy minimization phases then followed: 100 steepest
descent cycles, 1000 conjugate gradient cycles (until maximum deriv-
ative was less than 0.1 for both of them), 100 steepest descent cycles
(until maximum derivative was less than 0.01) and 2000 conjugate
gradient cycles (until maximum derivative was less than 0.0001).
3. Results and discussion
3.1. Immunological and protectivity studies
Critical residues from conserved, high-activity, binding pep-
tides were replaced by amino acids with similar mass but
di¡erent charge to render these peptides immunogenic and
protective since conserved sequences are not antigenic, nor
immunogenic. This paper tries to correlate these immunolog-
ical results with their three-dimensional structure.
Amino acid changes made to 4337, their capacity to induce
Table 1
Humoral immune response and protective e⁄cacy induced by 4337 and derived peptides in Aotus monkeys
14044 and 22158 have the same sequence and similar activity; this is due to 14044 being synthesized as a polymer (P) and 22158 synthesized as
a dendrimer (D). Peptide numbers given here correspond to those serial numbers used in our institute.
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antibodies as determined by IFA and their ability/inability to
induce protection are shown in Table 1.
Three peptides having a common amino acid sequence and
di¡erent forms of presentation were able to provide protec-
tion: 14044 (for which the three-dimensional structure was
determined) protected one out of ¢ve monkeys, with a 1:320
IFA titer after three doses. The same sequence in peptide
22158 synthesized as dendrimer fully protected ¢ve out of
10 monkeys with 1:160 antibody titer and with only two
doses. The same amino acid sequence, to which HTT was
added to the N-terminal sequence, in peptide 22822 protected
one monkey out of seven with a 1:1280 IFA titer with only
two immunizations. The speci¢c W1Y, G2S, E4M, H9L and
M15K modi¢cations (with or without extensions in the
N-termini, polymerized with cysteine or synthesized as den-
drimer) were thus able to protect seven out of 22 monkeys in
di¡erent assays. Assays included two peptides having di¡erent
formulations, but the same amino acid sequence. A third pep-
tide had the same amino sequence, elongated at the N-termi-
nal. 50 Aotus used as controls in the di¡erent experiments
were never protected.
Group B peptides (including peptide 14048 for which the
three-dimensional structure was determined) induced antibod-
ies with three doses, in 1:320 titers but did not protect mon-
keys against experimental challenge, suggesting di¡erences in
their IgG subclass or antibody a⁄nity. Changes made to 4337
peptide analogues from group C were not immunogenic, nor
protective.
The antibodies induced by the 14044, 22158 and 22822 pep-
tides in the protected monkeys recognized either the whole
116 kDa precursor, the 83/90 kDa doublet and its 36 and
22 kDa cleavage product range, or just some of them by
Western blot analysis (Fig. 1).
It can be concluded from these experiments that antibodies
elicited by immunization with 14044, 22158 and 22822 pep-
tides recognized functional, native and secondary structures in
the AMA-1 protein, as assessed by protection, IFA and West-
ern blot analysis respectively.
3.2. NMR
The presence of typical K-helix fragments in peptides 14044,
14048 and 13814 is supported by dNN(i,i+1), dKL(i,i+3),
dKN(i,i+3), dKN(i,i+4) NOE connectivity and low amide pro-
ton temperature coe⁄cients, as indicated by R in Fig. 2. The
latter data was used to determine hydrogen bond presence:
for peptide 14044 between K5 and L9 and A6 and T10; for
Fig. 1. Western blot analysis of P. falciparum schizont solubilized antigens showing protected Aotus sera reactivity with either the whole 116
kDa precursor, the 83/90 kDa doublet and its 36 and 22 kDa cleavage product range or just some of them. Pre-immune as well as non-pro-
tected sera are also shown.
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peptide 14048 between K5 and L9, R6 and T10, P12 and E16
and V13 and M17; and for peptide 13814 between K5 and
M9. Some long-range NOEs could be present (or not) in pep-
tide 13814 7^9 region, as a NOESY spectrum region was
found where there was signal overlap. It was decided to use
only that hydrogen bond de¢ned by the coe⁄cient of temper-
ature as very similar structures were de¢ned in calculations
with and without these NOEs and with and without a hy-
drogen bond. Lead peptide 4337 is not shown in Fig. 2 as it
did not show any long-range connectivity, displaying all
the sequential signals characterizing a lineal or random pep-
tide.
A set of 50 structures was calculated for the 14044 peptide
using 163 distance restraints, two hydrogen bond restraints
and 19 g dihedral angle restraints. 11 of the 50 structures
which did not have distance violation larger than 0.37 AV
nor dihedral angle violation greater than 1‡ were accepted.
These structures had 0.154 AV root mean square deviation
superimposition value for the backbone atoms (in red, Fig.
3, left panel). Six structures were then selected on the basis of
lowest total energy and agreement with experimental data
(Fig. 3, right panel). Kabash and Sander’s program [23] was
used to provide clearer analysis of how helical fragments were
de¢ned in the peptides. Structures were helical for peptide
14044 between residues 5 and 10 (corresponding to shaded
area in Table 2).
Results of structure calculations for peptides 14048 and
13814 are also shown in Table 2. If those structures de¢ned
Fig. 2. Summary of sequential and medium range NOEs represented by lines whose thickness is proportional to their NOE intensity. Low HN
amide temperature coe⁄cients are indicated by R and 3JHNHK indicated by c for: peptide 14044, peptide 14048, and peptide 13814.
Table 2
Summary of structure calculation results
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for peptides 14044 and 14048 are compared, a helical frag-
ment similar to residues 6^9 can be seen. Amino acid replace-
ments in peptide 14048 K17M and Y19W residue C-terminal
sequences helped to de¢ne a second helical fragment corre-
sponding to residues 13^16. A helical tendency appeared in
this peptide; but, the presence of proline in position 12 in the
middle of the helix produced a kink, causing a small turn
structure in residues 10^12.
It can be observed (Fig. 3, right panel) that in the 14044
immunogenic and protective peptide (W1Y, G2S, E4M, H9L
and M15K modi¢cations) the K-helix extends from K5 to
T10, maintaining high £exibility for the rest of the molecule.
In the immunogenic, but non-protective 14048 peptide (W1Y,
G2S, E4M, H9L, M15K and K17M modi¢cations) there are
two helical portions (R6^M9 and V13^E16), dramatically re-
ducing the peptide’s £exibility. In the non-protective, non-
antigenic 13814 peptide (W1Y, G2S, E4M and H9M modi¢-
cations) the K-helix goes from E3 to M9.
Fig. 3. Peptide 13814 (non-protective, non-immunogenic), 14048 (immunogenic, but non-protective) and 14044 (immunogenic and fully protec-
tive) structure. Left: Backbone representation of the same peptides. The core where the main modi¢cations were made is in red. Right: Ribbon
representation of the same fragment. Color code: A7 fuchsia; S8 red; L9 (14044, 14048), M9 (13814) pale blue; T10 dark blue; T11 pink; P12
brown; V13 white; L14 yellow; and K15 (14044, 14048), M15 (13814) green.
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We have tried to correlate those di¡erences observed in
peptides’ three-dimensional structure with immune response.
It can be observed that the changes in critical amino acids led
to conformational changes respecting native peptide possess-
ing random structure whilst helical fragments could be seen in
modi¢ed peptide. Our data suggests that a small helix in pep-
tide 14044 central region simultaneously produces antibodies
and also induces protection against P. falciparum experimen-
tal challenge of Aotus monkeys. In turn, this suggests a certain
degree of £exibility in the peptide thus enabling it to bind to
major histocompatibility complex^T-cell receptor (MHC^
TCR) immune system molecules. We have also observed
that this protection is lost when a peptide is less £exible
(14048) or when it has a helix in another region in the se-
quence (13814).
Although side chain conformation reliability is limited by a
relatively high conformational freedom, di¡erences in the res-
idues’ relative spatial assignment are clearly seen. Our data
shows clear di¡erences between peptides beginning in residue
A7 through residue 15, where the main changes were made in
the core of all peptides (Fig. 3, right panel). The modi¢cation
site and the concomitant change of con¢guration thus become
critical steps in the process of inducing appropriate immune
responses.
This data strongly suggests that amino acid changes, as well
as the relative residue orientation, may account for a better
interaction with immune system molecules possibly repairing
MHC^TCR interface defects.
Supporting our ¢ndings, it has recently been found that:
modi¢cations to an antagonist peptide were able to convert it
into an agonist one, repairing the defect in the TCR^peptide^
MHC-interface [24] ; that positive selection of CD4þ T-cells
was induced in vivo by agonist peptides whilst inhibited by
antagonist ones [25] ; and that some modi¢cations are more
potent than the wild type peptide [26], as we have shown here
and in a previous paper [13]. It has also been shown that this
type of modi¢cation is able to induce improved anti-tumor
immunity against AH1 colon^rectal carcinoma, stabilizing
this interface [27].
Our previous work and this paper strongly suggest that a
way to trigger an appropriate immune response is to speci¢-
cally modify conserved, non-immunogenic (antagonist) pep-
tides in speci¢c places (critical binding residues) to render
them immunogenic and protective (full agonist). This in
turn would facilitate the development of rational methodology
for obtaining multi-component subunit-based synthetic malar-
ial vaccines.
References
[1] Marsh, K. (1992) Parasitology 104, 553^559.
[2] Sachs, J. and Malaney, P. (2002) Nature 415, 680^685.
[3] Miller, L.H. and Ho¡man, S.L. (1998) Nat. Med. Vaccine Suppl.
4, 520^524.
[4] Miller, L.H., Baruch, D.I., Marsh, K. and Doumbo, O.K. (2002)
Nature 415, 673^679.
[5] Richie, T.L. and Saul, A. (2002) Nature 415, 694^701.
[6] Peterson, M.G., Marshall, V.M., Smythe, J.A., Crewther, P.E.,
Lew, A., Silva, A., Anders, R.F. and Kemp, D.J. (1989) Mol.
Cell. Biol. 9, 3151^3154.
[7] Narum, D.L. and Thomas, A.W. (1994) Mol. Biochem. Parasitol.
67, 59^68.
[8] Crewther, P.E., Culvenor, J.G., Silva, A., Cooper, J.A. and An-
ders, R.F. (1990) Exp. Parasitol. 70, 193^206.
[9] Marshall, D.L., Zhang, L., Anders, R.F. and Coppel, R.L. (1996)
Mol. Biochem. Parasitol. 77, 109^113.
[10] Hodder, A.N., Crewther, P.E. and Matthew, M.L. (1996) J. Biol.
Chem. 271, 29446^29452.
[11] Urquiza, M., Suarez, J.E., Cardenas, C., Lopez, R., Puentes, A.,
Chavez, F., Calvo, J.C. and Patarroyo, M.E. (2000) Vaccine 19,
508^513.
[12] Good, M.F., Pombo, D., Quakyi, I.A., Riley, E.M., Houghten,
R.A., Menon, A., Alling, D.W., Berzofsky, J.A. and Miller, L.H.
(1988) Proc. Natl. Acad. Sci. USA 85, 1199^1203.
[13] Espejo, F., Cubillos, M., Salazar, L.M., Guzman, F., Urquiza,
M., Ocampo, M., Silva, Y., Rodriguez, R., Lioy, E. and Patar-
royo, M.E. (2001) Angew. Chem. Int. Ed. 40, 4654^4657.
[14] Rodr|¤guez, R., Moreno, A., Guzma¤n, F., Calvo, M. and Patar-
royo, M.E. (1990) Am. J. Trop. Med. Hyg. 43, 339^354.
[15] Lambros, C. and Vanderberg, J.P. (1979) J. Parasitol. 65, 418^
420.
[16] Houghten, R.A. (1985) Proc. Natl. Acad. Sci. USA 82, 5131^
5135.
[17] Rivera, Z., Granados, G., Pinto, M., Varon, D., Carvajal, C.,
Chaves, F., Clavo, J., Rodriguez, R., Guzman, F. and Patarroyo,
M.E. (2002) J. Pept. Res. 59, 62^70.
[18] Waterhouse, V. and Johnson, C. (1994) Biochemistry 33, 2121^
2128.
[19] Rance, M., Sorensen, O.W., Bodenhausen, G., Wagner, G.,
Ernst, R.R. and Wu«thrich, K. (1983) Biochem. Biophys. Res.
Commun. 117, 479^485.
[20] Bax, A. and Davis, D.G. (1985) J. Magn. Res. 65, 355^360.
[21] Jeener, J., Meier, B.H., Backman, P. and Ernst, R.R. (1979)
J. Chem. Phys. 71, 4546^4553.
[22] Wu«thrich, K. (1986) NMR of Proteins and Nucleic Acids. John
Wiley and Sons, New York.
[23] Kabsch, W. and Sander, C. (1983) Biopolymers 22, 2577^2637.
[24] Baker, B.M., Gagnon, S.J., Biddison, W.E. and Wiley, D.C.
(2000) Immunity 13, 475^484.
[25] Tangri, S., Ishioka, G.Y., Huang, X., Sidney, J., Southwood, S.,
Fikes, J. and Sette, A. (2001) J. Exp. Med. 194, 833^846.
[26] Piotr, K., Pacholczyk, R., Ignatowicz, H., Kisielow, P., Jensen, P.
and Ignatowicz, L. (2001) J. Exp. Med. 194, 407^416.
[27] Slansky, J.E., Rattis, F.M., Boyd, L.F., Fahmy, T., Ja¡ee, E.M.,
Schneck, J.P., Margulies, D.H. and Pardoll, D.M. (2000) Immun-
ity 13, 529^538.
FEBS 26417 28-8-02 Cyaan Magenta Geel Zwart
L.M. Salazar et al./FEBS Letters 527 (2002) 95^100100
